## HCA: HCA Healthcare, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -1.3% below STRENGTH zone (3.0-6.0%); PEG 1.24 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-2.5% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($450.38)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 5, Bearish: 0)

**1. Jim Cramer on HCA Healthcare: “I Think It’s a Terrific One to Buy”**
- Source: Insider Monkey | 20251221T101400 | Bullish | Relevance: 100%
- Jim Cramer recommends HCA Healthcare due to its significant share buyback activity and consistent performance, despite a recent pullback. L1 Capital, while still invested, has trimmed its HCA holdings, noting increased share price and a less favorable risk-adjusted return potential compared to past opportunities. The article also suggests that certain AI stocks might offer higher returns in a shorter timeframe.

**2. Thrivent Financial for Lutherans Sells 3,039 Shares of HCA Healthcare, Inc. $HCA**
- Source: MarketBeat | 20251223T104613 | Somewhat-Bullish | Relevance: 100%
- Thrivent Financial for Lutherans significantly reduced its stake in HCA Healthcare Inc. by selling 3,039 shares, leaving them with 7,151 shares valued at $2.74 million. Other institutional investors also adjusted their holdings in HCA Healthcare. Analysts have issued a "Moderate Buy" consensus rating with a price target of $479.00 for the stock.

**3. Price Over Earnings Overview: HCA Healthcare**
- Source: Benzinga | 20251222T210833 | Neutral | Relevance: 100%
- HCA Healthcare Inc. (NYSE: HCA) shares are currently trading at $472.00, experiencing a slight decrease of 0.21% in the current session. While the stock has decreased by 8.48% over the past month, it has shown strong long-term performance with a 54.99% increase over the past year. The article highlights HCA Healthcare's Price-to-Earnings (P/E) ratio of 18.29, which is higher than the Health Care Providers & Services industry aggregate of 16.69, suggesting investors might expect better future performance or that the stock could be overvalued.

**4. Jim Cramer on HCA Healthcare: “I think it’s a terrific one to buy”**
- Source: MSN | 20251221T150749 | Bullish | Relevance: 100%
- Jim Cramer of CNBC's "Mad Money" recommended HCA Healthcare, stating it's a terrific stock to buy. He highlighted the company's attractive valuation and strong position in the healthcare sector as key reasons for his bullish outlook. Cramer's endorsement signals confidence in HCA Healthcare's future performance.

**5. HCA Healthcare, Inc. $HCA Shares Sold by Wedge Capital Management L L P NC**
- Source: MarketBeat | 20251221T123513 | Bullish | Relevance: 100%
- Wedge Capital Management L L P NC reduced its stake in HCA Healthcare by 16.4%, selling 17,374 shares and now holding 88,410 shares valued at $37.68 million. The company exceeded Q3 expectations with an EPS of $6.96 versus a $5.64 consensus and revenue of $19.16 billion, setting FY2025 guidance at $27.00–$28.00 EPS. Analysts maintain a "Moderate Buy" rating with a $479 target, and HCA declared a quarterly dividend of $0.72 per share.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-18 | Mizuho | $520 | $505 | +3% |
| 2025-12-15 | Morgan Stanley | $425 | $425 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-18 | Mizuho | main | Outperform |
| 2025-12-15 | Morgan Stanley | down | Underweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 2 ($3.12M) |
| Sells | 4 ($14.79M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 29.8% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 2 / 7 |

**Top Holders:**
- Vanguard Group Inc: 6.5% (-3.8%)
- Blackrock Inc.: 5.5% (-3.7%)
- Sanders Capital, LLC: 4.7% (-3.9%)
- State Street Corpora: 3.3% (-5.9%)
- JPMORGAN CHASE & CO: 2.6% (+82.2%)

### Key Risks

1. Momentum deterioration: MRS_10 falling (-2.5% 5d) with bearish MACD, trend may be turning.
2. Heavy insider selling: $15M sold (4 transactions in 90 days).
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.24 suggests fair value with growth premium. Forward P/E 15.9x stretched relative to 7% growth. Quality metrics strong (ROE 136%, ROA 12%). Balance sheet: $3.1B free cash flow. Insider selling cluster ($14.8M in 90 days), potential headwind. Institutional flow bullish (2 buying vs 7 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $110.9B |
| Beta | 1.37 |
| 52W Range | $289.98 - $520.00 |
| Short Interest | 3.1% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.24 |
| Forward P/E | 15.9 |
| Current P/E | 17.1 |
| YoY Growth | 7.3% |
| EPS Direction | RISING |

### Technicals

MRS_10 deteriorating from 1.2% to -1.3% (-2.5% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 4.3pp (needs >3.0% for momentum thesis). Long-term uptrend intact (above SMA200 at 1.19x) but short-term weakness (below SMA20). MACD histogram bearish (-2.90), momentum weakening. RSI neutral at 48. OFD pattern: +MTL (Rally).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -1.27% (CS: 45) | Neutral |
| RSI_14 | 47.7 | Neutral |
| MACD Histogram | -2.90 | Bearish |
| vs SMA20 | 0.975x | Below |
| vs SMA50 | 1.007x | Above |
| vs SMA200 | 1.193x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $473.88
- **Stop Loss:** $450.38 (5.0% risk)
- **Target:** $497.38 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 51
- **Position Value:** $24,167.88
- **Portfolio %:** 24.17%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate risk appetite in holiday-thinned conditions. VIX at 52-week lows suggests complacency, but modest breadth improvement and stable yields indicate underlying stability. Focus on quality positioning ahead of 2026 catalysts.*

### Earnings

**Next:** 2026-01-23 (Est: $7.46)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $5.73 | $6.96 | +21.6% |
| 2025Q2 | $6.32 | $6.84 | +8.2% |
| 2025Q1 | $5.75 | $6.45 | +12.1% |
| 2024Q4 | $6.14 | $6.22 | +1.2% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*